How We Help Researchers
Want to work with us? We are happy to share our robust data set with research collaborators in order to co-publish findings. We have over 17 thousand EPIC 850k longitudinal methylation profiles from consenting patients, including covariates like disease history and medication use.
Need specialized data for your study? We can reach out to our patient cohort to get additional information.
Example:When Cornell University researchers published on COVID-19 early in the pandemic, we thought they might be interested in using our data on the topic for additional investigation.
Together, we decided to look at longitudinal methylation changes before and after COVID-19 and mRNA vaccines. TruDiagnostic supplied longitudinal datasets on over 60 patients.
Cornell took the lead on analyzing the data, but was later joined by the Yale research team for additional insight. The final paper was submitted and published in 2021.
We may be able to work together at a discount, or even no cost to you!
We love to partner with academic institutions and sponsor research endeavors, in exchange for exclusivity on intellectual property.
In our collaboration with Harvard University researchers, we agreed to use a multi-omic dataset to generate the most robust phenotypic and death predictor to date.
After initiating a multi-million dollar sponsored research agreement with Channing lab and Partners Biobank, TruDiagnostic started testing the 5,000 samples from the biobank for metabolomic and epigenomic data. We recently began testing 1,500 plasma samples with our TruDiagnostic Imprintome Chip, aided by the Seer Proteograph.
With 1,488 defined ICRs and 23,000 CpGs; as of May this is the third-largest proteomic analysis project in the world, using the most complete human imprintome array in the world.
By the end of 2022, we hope to create a Proteomic Age Clock, Metabolomic Age Clock, Epigenetic Phenotypic Multiomic Age Clock, and a Epigenetic Death Trained Multiomic Clock
TruDiagnostic is sponsoring this effort, in exchange for exclusivity on IP developed through the project.
For joint research endeavors in research partnerships, we can provide discounted or free methylation testing for joint investigations.
Example:Scientists at the Ohio State University Cancer Center reached out to test 700 samples at our lab, from cancer patients. Given the other covariate data they had, TruDiagnostic offered to sponsor 50% of the testing cost in exchange for research collaboration.
We will now be processing over 1,200 samples with the expanded budget, with shared data for analysis on the methylation and aging associations with clinical outcomes.
Once analysis is complete, we plan to publish this analysis on the effects of epigenetic age and cancer. We also hope to discover novel areas of methylation change with senescent data and create T-Cell specific aging algorithms.
TruDiagnostic is HIPAA compliant.
Data sharing requires completion of a research agreement, like MOU and MDTA.
Any data used for research collaboration is de-identified, so personal information will never be shared with any third party.
We have a robust data set of over 15,000 patients who have completed our TruAge testing, who have consented for their de-identified data to be used for research purposes.
Approximately 20% of these individuals have completed multiple tests, with covariate data updated each time.
We collect a wide array of health and behavior-related covariates from consenting patients. These covariates include information like medication history, supplement use, disease diagnosis, cancer history, lifestyle habits like sleep, diet, stress, caffiene and alcohol use, and much more.
Additionally, many have consented to be contacted for additional questions.
The majority of financial cost involved in research studies often comes from recruitment of patients, testing, and analysis of samples.
Our established database of consenting patients can help reduce this cost.
If you're looking for data that isn't in research cohorts, or you want a validation dataset, we can help with data from our own database and recruitment of patients from our physician network.
Additionally, we can often recruit patients who are testing with us in the future to collect custom data at their time of testing that we wouldn't normally collect.
TruDiagnostic is invested in new data generation, so we often sponsor research projects.
Sponsored research requires completion of a research agreement (eg, MOU and MDTA, if applicable) We can sponsor costs for methylation testing with our EPIC850k array, proteomic testing on the Seer platform, RNA-sequening, Genomic processing services, and our bioinformatics analysis.
To support advanced analysis, our bioinformatics team can help examine your resultant data for useful information and trends. With sponsored research projects, we typically expect exclusive IP rights for products that are developed as a result of our labwork.
We offer affordable sample processing, validation cohort data sharing, and data analysis services for those who use us as their third-party lab.
Often, we can offer this at steeply discounted or no-cost rates in research collaborations.
Joint SBIR / STTR Applications
TruDiagnostic is dedicated to the advancement of science, with a team dedicated to preparing and submitting grant applications.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants are the U.S government's funding mechanism that is open to small businesses.
Non-profit partners can be included as consultants or sub-awardees.
We can take the lead in drafting grant proposals for your project, with your review and input.
Create new algorithms, share data, and further explore the impact of epigenetics on health outcomes. TruDiagostic frequently partners with universities and private companies for epigenetic and proteomic research.
Whether you're a for-profit company, an academic research institution, or a non-profit, we'd be happy to learn about your research project: maybe we can help!
TruDiagnostic started commercial epigenetic age testing in July 2020. Since then, we have tested over 15,000 patients on the EPIC850k array.
Our 20,000 sq ft, CLIA-Certified laboratory has hosted over 30 institutional research board approved clinical trials. Our team has developed 3 custom methylation arrays for aging and the imprintome as of May 2022.
We have developed custom deconvolution algorithms, telomere estimators, mitotic clocks, multi-omic age clocks, and more.